Product Profiles: Pipeline Antibacterials - Gram-negative combination antibiotics show promise in MRSA-focused pipeline
Datamonitor, January 2012, Pages: 111
The majority of the drugs in the late stage of the pipeline are being developed to target Gram-positive infections, including methicillin-resistant Staphylococcus aureus (MRSA). Progress has been slow, with many drugs held up by the US FDA's changing guidance on the design of antibiotic clinical trials. If successful, agents will be entering a large, but increasingly crowded, anti-MRSA market.
Scope:
- Extensive analysis of clinical trial data and assessment of clinical and commercial attractiveness for pipeline antibacterials
- Discussion of future strategic opportunities to achieve success in an increasingly crowded antibacterials market
- Analysis of the ability of pipeline drugs to satisfy key unmet needs in the antibacterials space
Highlights:
- Two promising antibacterials were launched in the US in 2011. Teflaro is the first cephalosporin to target MRSA, but enters an increasingly crowded market. Dificid is only the second drug in the US to be approved for Clostridium difficile-associated diarrhea, demonstrating reduced rates of relapse, however high pricing may prevent rapid uptake.
- Several antibiotics are in late stage development that target MRSA, from oral once daily drugs, to antibiotics that require only one or two doses per treatment course. Their convenience and potential to save significant hospital resources makes them very attractive therapies, but each will compete to reach the market first.
- Two highly anticipated combination therapies targeting serious Gram-negative infections, including multidrug-resistant pathogens, entered Phase III in 2011. If approved, they will be direct competitors as both cover many of the same organisms, but one has the ability to meet specific key unmet needs better than the other.
Reasons to buy:
- Identify key drugs within the antibacterials pipeline, success factors for recently launched brands, and the potential for new entrant products.
- Assess strengths, weaknesses, opportunities and threats of key pipeline antibacterials and how they influence clinical and commercial attractiveness.
- Understand the impact of events such as changing FDA guidances on clinical trial design, and successful and unsuccessful partnership deals.
OVERVIEW
Catalyst
Summary
EXECUTIVE SUMMARY
Strategic scoping and focus
Datamonitor key findings
Related reports
PRODUCT OVERVIEW
Key pipeline products for antibacterials
PIPELINE PRODUCT PROFILES
Teflaro/Zinforo (ceftaroline fosamil; Forest Laboratories/AstraZeneca)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Dificid/Dificlir (fidaxomicin; Optimer Pharmaceuticals/Astellas Pharma)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Tedizolid phosphate (Trius Therapeutics/Dong-A Pharmaceutical/Bayer)
Drug profile
Development overview
Ongoing clinical trials
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
PTK 0796 (Paratek Pharmaceuticals)
Drug profile
Development overview
Ongoing clinical trials
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Dalbavancin (Durata Therapeutics)
Drug profile
Development overview
Ongoing clinical trials
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Oritavancin (The Medicines Company)
Drug profile
Development overview
Ongoing clinical trials
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
CXA-201 (CXA-101/tazobactam; Cubist Pharmaceuticals)
Drug profile
Development overview
Ongoing clinical trials
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
CAZ-AVI (ceftazidime/avibactam; Forest Laboratories/AstraZeneca)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Other pipeline antibacterials
CB-183,315 (Cubist Pharmaceuticals)
Delafloxacin (Rib-X)
BC-3781 (Nabriva Therapeutics)
TP-434 (Tetraphase Pharmaceuticals)
Ceftaroline/avibactam (ceftaroline/avibactam; Forest Laboratories/AstraZeneca)
PMX-30063 (PolyMedix)
GSK-052 (Anacor Pharmaceuticals/GlaxoSmithKline)
Ceftobiprole (Basilea Pharmaceutica)
Cethromycin (Advanced Life Sciences)
BIBLIOGRAPHY
Journal papers
Websites
Datamonitor reports
APPENDIX
PharmaVitae Explorer database
Contributing experts
Conferences attended
Report methodology
TABLES
Table: Key pipeline products for antibacterials,
Table: Teflaro/Zinforo (ceftaroline fosamil; Forest laboratories/AstraZeneca) – drug profile,
Table: Summary of the pivotal Phase III clinical trials for Teflaro/Zinforo ( c eftaroline fosamil) in the treatment of ABSSSIs and CABP,
Table: Ability of Teflaro/Zinforo (ceftaroline fosamil) to meet unmet needs,
Table: Datamonitor drug assessment summary of Teflaro/Zinforo (ceftaroline fosamil; Forest Laboratories/AstraZeneca),
Table: Dificid/Dificlir (fidaxomicin; Optimer Pharmaceuticals/Astellas Pharma) – drug profile,
Table: Summary of the key Phase III clinical trials for Dificid/Dificlir (fidaxomicin) in the treatment of CDAD,
Table: Ability of Dificid/Dificlir (fidaxomicin) to meet unmet needs,
Table: Datamonitor drug assessment summary of Dificid/Dificlir (fidaxomicin; Optimer Pharmaceuticals/Astellas Pharma),
Table: Tedizolid phosphate (Trius Therapeutics/Dong-A Pharmaceutical/Bayer) – drug profile,
Table: Summary of the key Phase II clinical trial for tedizolid phosphate (TR-701) in the treatment of cSSSI,
Table: Phase III trial (TR701-113) to determine the efficacy of intravenous to oral TR-701 versus intravenous to oral linezolid in ABSSSIs,
Table: Ability of tedizolid phosphate (TR-701) to meet unmet needs,
Table: Datamonitor drug assessment summary of tedizolid phosphate (Trius Therapeutics/Dong-A Pharmaceutical/Bayer),
Table: PTK 0796 (Paratek Pharmaceuticals) – drug profile,
Table: Summary of the key Phase II clinical trial for PTK 0796 in the treatment of cSSSI,
Table: Ability of PTK 0796 to meet unmet needs,
Table: : Datamonitor drug assessment summary of PTK 0796 (Paratek Pharmaceuticals),
Table: Dalbavancin (Durata Therapeutics) – drug profile,
Table: Summary of early Phase III clinical trials for dalbavancin in the treatment of cSSSI,
Table: Phase III trials (DISCOVER-1 and DISCOVER-2) to determine the efficacy of dalbavancin versus vancomycin and linezolid in ABSSSI,
Table: Ability of dalbavancin to meet unmet needs,
Table: Datamonitor drug assessment summary of dalbavancin (Durata Therapeutics),
Table: Oritavancin (The Medicines Company) – drug profile,
Table: Summary of early key Phase III clinical trials for oritavancin in the treatment of cSSSI,
Table: Phase III trials (SOLO I and SOLO II) to determine the efficacy of oritavancin versus vancomycin in ABSSSI,
Table: Ability of oritavancin to meet unmet needs,
Table: Datamonitor drug assessment summary of oritavancin (The Medicines Company),
Table: CXA-201 (CXA-101/tazobactam; Cubist Pharmaceuticals) – drug profile,
Table: Summary of the key Phase II clinical trials for CXA-101 and CXA-201 (CXA-101/tazobactam) in the treatment of cUTIs and cIAIs,
Table: Phase III trials (CXA-cUTI-10-04 and CXA-cUTI-10-05) to determine the efficacy of CXA-201 versus levofloxacin in cUTI,
Table: Phase III trials (CXA-cIAI-10-08 and CXA-cIAI-10-09) to determine the efficacy of CXA-201 versus meropenem in cIAI,
Table: Ability of CXA-201 (CXA-101/tazobactam) to meet unmet needs,
Table: Datamonitor drug assessment summary of CXA-201 (CXA-201/tazobactam; Cubist Pharmaceuticals),
Table: CAZ-AVI (ceftazidime/avibactam; Forest Laboratories/AstraZeneca) – drug profile,
Table: Summary of the key Phase II clinical trials for CAZ-AVI (ceftazidime/avibactam) in the treatment of cIAIs and cUTIs,
Table: Ability of CAZ-AVI (ceftazidime/avibactam) to meet unmet needs,
Table: Datamonitor drug assessment summary of CAZ-AVI (ceftazidime/avibactam; Forest Laboratories/AstraZeneca),
FIGURES
Figure: Teflaro/Zinforo (ceftaroline fosamil; Forest Laboratories/AstraZeneca) – SWOT analysis,
Figure: Datamonitor drug assessment summary of Teflaro/Zinforo (ceftaroline fosamil; Forest Laboratories/AstraZeneca),
Figure: Dificid/Dificlir (fidaxomicin; Optimer Pharmaceuticals/Astellas Pharma) – SWOT analysis,
Figure: Datamonitor drug assessment summary of Dificid/Dificlir (fidaxomicin; Optimer Pharmaceuticals/Astellas Pharma),
Figure: Tedizolid phosphate (Trius Therapeutics/Dong-A Pharmaceutical/Bayer) – SWOT analysis,
Figure: Datamonitor drug assessment summary of tedizolid phosphate (Trius Therapeutics/Dong-A Pharmaceutical/Bayer),
Figure: Phase II trial of PTK 0796 versus linezolid in treatment of complicated skin and skin structure infections,
Figure: PTK 0796 (Paratek Pharmaceuticals) – SWOT analysis,
Figure: Datamonitor drug assessment summary of PTK 0796 (Paratek Pharmaceuticals),
Figure: Dalbavancin (Durata Therapeutics) – SWOT analysis,
Figure: Datamonitor drug assessment summary of dalbavancin (Durata Therapeutics),
Figure: Oritavancin (The Medicines Company) – SWOT analysis,
Figure: Datamonitor drug assessment summary of oritavancin (The Medicines Company),
Figure: CXA-201 (CXA-101/tazobactam; Cubist Pharmaceuticals) – SWOT analysis,
Figure: Datamonitor drug assessment summary of CXA-201 (CXA-201/tazobactam; Cubist Pharmaceuticals),
Figure: CAZ-AVI (ceftazidime/avibactam; Forest Laboratories/AstraZeneca) – SWOT analysis,
Figure: Datamonitor drug assessment summary of CAZ-AVI (ceftazidime/avibactam; Forest Laboratories/AstraZeneca),
Figure: The PharmaVitae Explorer
- Abbott Laboratories
- Delta Air Lines, Inc.
- Devoteam SA
- GlaxoSmithKline Plc
- Health Protection Agency
- Hutchison 3G UK Limited
- Johnson & Johnson
- Novartis AG
- Texas Instruments Incorporated
- The Medicines Company
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
